Cargando…

Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study

BACKGROUND: Splanchnic vein thrombosis (SVT) is a major complication of moderate and severe acute pancreatitis. There is no consensus on whether therapeutic anticoagulation should be started in patients with acute pancreatitis and SVT. AIM: To gain insight into current opinions and clinical decision...

Descripción completa

Detalles Bibliográficos
Autores principales: Sissingh, Noor J, Groen, Jesse V, Timmerhuis, Hester C, Besselink, Marc G, Boekestijn, Bas, Bollen, Thomas L, Bonsing, Bert A, Klok, Frederikus A, van Santvoort, Hjalmar C, Verdonk, Robert C, van Eijck, Casper H J, van Hooft, Jeanin E, Mieog, Jan Sven D
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Baishideng Publishing Group Inc 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292147/
https://www.ncbi.nlm.nih.gov/pubmed/37377583
http://dx.doi.org/10.3748/wjg.v29.i21.3328
_version_ 1785062826680778752
author Sissingh, Noor J
Groen, Jesse V
Timmerhuis, Hester C
Besselink, Marc G
Boekestijn, Bas
Bollen, Thomas L
Bonsing, Bert A
Klok, Frederikus A
van Santvoort, Hjalmar C
Verdonk, Robert C
van Eijck, Casper H J
van Hooft, Jeanin E
Mieog, Jan Sven D
author_facet Sissingh, Noor J
Groen, Jesse V
Timmerhuis, Hester C
Besselink, Marc G
Boekestijn, Bas
Bollen, Thomas L
Bonsing, Bert A
Klok, Frederikus A
van Santvoort, Hjalmar C
Verdonk, Robert C
van Eijck, Casper H J
van Hooft, Jeanin E
Mieog, Jan Sven D
author_sort Sissingh, Noor J
collection PubMed
description BACKGROUND: Splanchnic vein thrombosis (SVT) is a major complication of moderate and severe acute pancreatitis. There is no consensus on whether therapeutic anticoagulation should be started in patients with acute pancreatitis and SVT. AIM: To gain insight into current opinions and clinical decision making of pancreatologists regarding SVT in acute pancreatitis. METHODS: A total of 139 pancreatologists of the Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group were approached to complete an online survey and case vignette survey. The threshold to assume group agreement was set at 75%. RESULTS: The response rate was 67% (n = 93). Seventy-one pancreatologists (77%) regularly prescribed therapeutic anticoagulation in case of SVT, and 12 pancreatologists (13%) for narrowing of splanchnic vein lumen. The most common reason to treat SVT was to avoid complications (87%). Acute thrombosis was the most important factor to prescribe therapeutic anticoagulation (90%). Portal vein thrombosis was chosen as the most preferred location to initiate therapeutic anticoagulation (76%) and splenic vein thrombosis as the least preferred location (86%). The preferred initial agent was low molecular weight heparin (LMWH; 87%). In the case vignettes, therapeutic anticoagulation was prescribed for acute portal vein thrombosis, with or without suspected infected necrosis (82% and 90%), and thrombus progression (88%). Agreement was lacking regarding the selection and duration of long-term anticoagulation, the indication for thrombophilia testing and upper endoscopy, and about whether risk of bleeding is a major barrier for therapeutic anticoagulation. CONCLUSION: In this national survey, the pancreatologists seemed to agree on the use of therapeutic anticoagulation, using LMWH in the acute phase, for acute portal thrombosis and in the case of thrombus progression, irrespective of the presence of infected necrosis.
format Online
Article
Text
id pubmed-10292147
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher Baishideng Publishing Group Inc
record_format MEDLINE/PubMed
spelling pubmed-102921472023-06-27 Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study Sissingh, Noor J Groen, Jesse V Timmerhuis, Hester C Besselink, Marc G Boekestijn, Bas Bollen, Thomas L Bonsing, Bert A Klok, Frederikus A van Santvoort, Hjalmar C Verdonk, Robert C van Eijck, Casper H J van Hooft, Jeanin E Mieog, Jan Sven D World J Gastroenterol Observational Study BACKGROUND: Splanchnic vein thrombosis (SVT) is a major complication of moderate and severe acute pancreatitis. There is no consensus on whether therapeutic anticoagulation should be started in patients with acute pancreatitis and SVT. AIM: To gain insight into current opinions and clinical decision making of pancreatologists regarding SVT in acute pancreatitis. METHODS: A total of 139 pancreatologists of the Dutch Pancreatitis Study Group and Dutch Pancreatic Cancer Group were approached to complete an online survey and case vignette survey. The threshold to assume group agreement was set at 75%. RESULTS: The response rate was 67% (n = 93). Seventy-one pancreatologists (77%) regularly prescribed therapeutic anticoagulation in case of SVT, and 12 pancreatologists (13%) for narrowing of splanchnic vein lumen. The most common reason to treat SVT was to avoid complications (87%). Acute thrombosis was the most important factor to prescribe therapeutic anticoagulation (90%). Portal vein thrombosis was chosen as the most preferred location to initiate therapeutic anticoagulation (76%) and splenic vein thrombosis as the least preferred location (86%). The preferred initial agent was low molecular weight heparin (LMWH; 87%). In the case vignettes, therapeutic anticoagulation was prescribed for acute portal vein thrombosis, with or without suspected infected necrosis (82% and 90%), and thrombus progression (88%). Agreement was lacking regarding the selection and duration of long-term anticoagulation, the indication for thrombophilia testing and upper endoscopy, and about whether risk of bleeding is a major barrier for therapeutic anticoagulation. CONCLUSION: In this national survey, the pancreatologists seemed to agree on the use of therapeutic anticoagulation, using LMWH in the acute phase, for acute portal thrombosis and in the case of thrombus progression, irrespective of the presence of infected necrosis. Baishideng Publishing Group Inc 2023-06-07 2023-06-07 /pmc/articles/PMC10292147/ /pubmed/37377583 http://dx.doi.org/10.3748/wjg.v29.i21.3328 Text en ©The Author(s) 2023. Published by Baishideng Publishing Group Inc. All rights reserved. https://creativecommons.org/licenses/by-nc/4.0/This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
spellingShingle Observational Study
Sissingh, Noor J
Groen, Jesse V
Timmerhuis, Hester C
Besselink, Marc G
Boekestijn, Bas
Bollen, Thomas L
Bonsing, Bert A
Klok, Frederikus A
van Santvoort, Hjalmar C
Verdonk, Robert C
van Eijck, Casper H J
van Hooft, Jeanin E
Mieog, Jan Sven D
Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study
title Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study
title_full Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study
title_fullStr Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study
title_full_unstemmed Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study
title_short Therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: A national survey and case-vignette study
title_sort therapeutic anticoagulation for splanchnic vein thrombosis in acute pancreatitis: a national survey and case-vignette study
topic Observational Study
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10292147/
https://www.ncbi.nlm.nih.gov/pubmed/37377583
http://dx.doi.org/10.3748/wjg.v29.i21.3328
work_keys_str_mv AT sissinghnoorj therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT groenjessev therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT timmerhuishesterc therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT besselinkmarcg therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT boekestijnbas therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT bollenthomasl therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT bonsingberta therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT klokfrederikusa therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT vansantvoorthjalmarc therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT verdonkrobertc therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT vaneijckcasperhj therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT vanhooftjeanine therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy
AT mieogjansvend therapeuticanticoagulationforsplanchnicveinthrombosisinacutepancreatitisanationalsurveyandcasevignettestudy